DNA Therapeutics
PrivateLast Round
M&A
Mar 28, 2016
Total Funding Raised
$4M
Company Overview
DNA Therapeutics is a biotechnology company that develops targeted drugs for sensitizing resistant cancer to conventional cancer therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DNA Therapeutics Comparables
Compare DNA Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valerio Therapeutics | 87% | |
| Artios Pharma | 80% | |
| Onco-Innovations | 79% | |
DNA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Mar 28, 2016 | ||||
| Series A | Jan 29, 2009 | ||||
| Seed | Nov 6, 2008 |
DNA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Inserm Transfert | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 32% MoM.
- Apr 17, 2026
Monthly visitors grew 71% MoM, from 308 to 528.
DNA Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about DNA Therapeutics's valuation, stock price, and market status.